SRC
ALIM

Shufro Rose & Co’s Alimera Sciences ALIM Stock Holding History

Shufro Rose & Co’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-667
Closed -$9K – 349
2019
Q2 		$9K Hold
667
– – ﹤0.01% 304
2019
Q1 		$11K Hold
667
– – ﹤0.01% 296
2018
Q4 		$7K Hold
667
– – ﹤0.01% 295
2018
Q3 		$10K Hold
667
– – ﹤0.01% 296
2018
Q2 		$10K Hold
667
– – ﹤0.01% 297
2018
Q1 		$10K Hold
667
– – ﹤0.01% 303
2017
Q4 		$13K Hold
667
– – ﹤0.01% 288
2017
Q3 		$14K Hold
667
– – ﹤0.01% 288
2017
Q2 		$14K Hold
667
– – ﹤0.01% 267
2017
Q1 		$14K Buy
+667
New +$12.8K ﹤0.01% 271

Other funds holding ALIM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Shufro Rose & Co's ALIM Position: Q3 2019 in Review

Shufro Rose & Co sold out of Alimera Sciences (ALIM) in Q3 2019, closing a stake of 667 shares — an estimated $9K sold.

Shufro Rose & Co first reported a position in ALIM in Q1 2017 and held it in 10 quarters. The position peaked at $14K in Q3 2017. 32 funds tracked by Wall St. Rank hold ALIM as of Q3 2019.

  • Shufro Rose & Co reported no remaining Alimera Sciences position as of Q3 2019 after selling out during the quarter.
  • Shufro Rose & Co sold 667 Alimera Sciences shares in Q3 2019, an estimated $9K.
  • Shufro Rose & Co first reported a position in Alimera Sciences in Q1 2017 and held it in 10 quarters.
  • Shufro Rose & Co's Alimera Sciences position peaked at $14K in Q3 2017.
  • 32 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2019.

Based on Shufro Rose & Co's 13F filing for Q3 2019, filed 30 Oct 2019.